Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | CASP6 | P55212 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 4/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | SCN4A | P35499 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.39 |
| ▸ | TYR | P14679 | 1/20 | 0.39 |
| ▸ | UGT2B7 | P16662 | 1/20 | 0.38 |
| ▸ | CCR1 | P32246 | 1/20 | 0.38 |
| ▸ | CCR5 | P51681 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17257443 | 0.86 | CYP1A2 (0.57) | CYP1A2LMNAKDM4EPOLBCASP6 | |
| SCHEMBL12436949 | 0.85 | CYP1A2 (0.52) | CYP1A2LMNAKDM4EPOLBCASP6 | |
| SCHEMBL24654879 | 0.85 | CYP1A2 (0.55) | CYP1A2LMNAKDM4EPOLBCASP6 | |
| SCHEMBL31201745 | 0.85 | CYP1A2 (0.55) | CYP1A2LMNAKDM4EPOLBCASP6 | |
| SCHEMBL24253561 | 0.85 | CYP1A2 (0.55) | CYP1A2LMNAKDM4EPOLBCASP6 | |
| SCHEMBL27684616 | 0.80 | CYP1A2 (0.50) | CYP1A2LMNAKDM4EPOLBCASP6 | |
| SCHEMBL27684617 | 0.80 | CYP1A2 (0.50) | CYP1A2LMNAKDM4EPOLBCASP6 | |
| SCHEMBL889349 | 0.80 | NPC1 (0.43) | CYP1A2LMNAKDM4EPOLBCASP6 | |
| SCHEMBL21195656 | 0.80 | NPC1 (0.43) | CYP1A2LMNAKDM4ERAB9ANPC1 | |
| SCHEMBL10122186 | 0.80 | NPC1 (0.43) | CYP1A2LMNAKDM4ERAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-20240199604-A1 | SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-06-20 | — | — | US | disclosed |
| US-11820766-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-11820766-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| EP-4249486-A1 | ALBICIDIN DERIVATIVES, THEIR USE AND SYNTHESIS | Technische Universität Berlin (DE) | 2023-09-27 | — | — | EP | disclosed |
| US-20220220111-A1 | 1,8-NAPHTHYRIDINONE COMPOUNDS AND USES THEREOF | NUVATION BIO OPERATING COMPANY INC (US) | 2022-07-14 | — | — | US | disclosed |
| US-20220153724-A1 | Inhibitors Of Plasma Kallikrein | KALVISTA PHARMACEUTICALS LTD (GB) | 2022-05-19 | — | — | US | disclosed |
| US-20220119367-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | INTEGRAL BIOSCIENCES PVT. LTD. (IN) | 2022-04-21 | — | — | US | disclosed |
| US-11242333-B2 | Inhibitors of plasma kallikrein | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2022-02-08 | — | — | US | disclosed |
| US-20210292285-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | NUVATION BIO INC (US) | 2021-09-23 | — | — | US | disclosed |
| US-20080249130-A1 | Gut microsomal triglyceride transport protein inhibitors | SIRTRIS PHARMACEUTICALS, INC. (US) | 2008-10-09 | — | — | US | disclosed |
| US-20070232648-A1 | MODULATORS OF THE GLUCOCORTICOID RECEPTOR AND METHOD | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-04 | — | — | US | disclosed |
| US-20070232648-A1 | MODULATORS OF THE GLUCOCORTICOID RECEPTOR AND METHOD | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-04 | — | — | US | disclosed |
| WO-2007027855-A2 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2007-03-08 | — | — | WO | disclosed |
| US-20070049603-A1 | Raf inhibitor compounds and methods of use thereof | ARRAY BIOPHARMA INC. | 2007-03-01 | — | — | US | disclosed |
| EP-0818512-B1 | Quinoline derivative and use of same | MITSUI CHEMICALS INC (JP) | 2002-10-02 | — | — | EP | disclosed |
| US-6407242-B1 | REACTING A PHTHALIMIDE COMPOUND WITH A QUINOLINE COMPOUND;ELECTROLUMINESCENCE | MITSUI CHEMICALS, INC. (JP) | 2002-06-18 | — | — | US | disclosed |
| US-6132640-A | ZINC COMPLEXES OF QUINOLINE | MITSUI CHEMICALS, INC. (JP) | 2000-10-17 | — | — | US | disclosed |
| EP-0818512-A1 | Quinoline derivative and use of same | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1998-01-14 | — | — | EP | disclosed |
| US-4207320-A | FUNGICIDES | WARNER-LAMBERT COMPANY (US) | 1980-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199604-A1 | SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS | MAPT, HTT, PSEN1 | CYP1A2 4855/4885LMNA 1102/4885KDM4E 4298/4885 |
| US-20220153724-A1 | Inhibitors Of Plasma Kallikrein | KLKB1, SERPINB1, KLK5 | CYP1A2 2968/4885LMNA 110/4885KDM4E 1741/4885 |
| US-20070049603-A1 | Raf inhibitor compounds and methods of use thereof | BRAF, RAF1, ARAF | CYP1A2 3344/4885LMNA 1333/4885KDM4E 3956/4885 |
| US-11242333-B2 | Inhibitors of plasma kallikrein | KLKB1, SERPINB1, KLK5 | CYP1A2 2968/4885LMNA 110/4885KDM4E 1741/4885 |
| US-20220220111-A1 | 1,8-NAPHTHYRIDINONE COMPOUNDS AND USES THEREOF | NME1, ADORA2A, GPR68 | CYP1A2 2705/4885LMNA 2012/4885KDM4E 3184/4885 |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | CYP1A2 4854/4885LMNA 2696/4885KDM4E 1450/4885 |
| US-20070232648-A1 | MODULATORS OF THE GLUCOCORTICOID RECEPTOR AND METHOD | NR3C1, NR3C2, MC2R | CYP1A2 1208/4885LMNA 4761/4885KDM4E 3282/4885 |
| US-20220119367-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | ADORA2A, ADORA3, ADORA1 | CYP1A2 3003/4885LMNA 4458/4885KDM4E 4200/4885 |
| US-20210292285-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | ADORA2A, ADORA3, ADORA1 | CYP1A2 3003/4885LMNA 4458/4885KDM4E 4200/4885 |
| US-20080249130-A1 | Gut microsomal triglyceride transport protein inhibitors | MTTP, CETP, FABP2 | CYP1A2 80/4885LMNA 3896/4885KDM4E 2386/4885 |
| US-11820766-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | CYP1A2 540/4885LMNA 1308/4885KDM4E 2437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.